About septerna inc - SEPN
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
SEPN At a Glance
Septerna, Inc.
250 East Grand Avenue
South San Francisco, California 94080
| Phone | 1-650-338-3533 | Revenue | 45.95M | |
| Industry | Biotechnology | Net Income | -48,879,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 4,174.512% | |
| Fiscal Year-end | 12 / 2026 | Employees | 130 | |
| View SEC Filings |
SEPN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 26.853 |
| Price to Book Ratio | 3.271 |
| Price to Cash Flow Ratio | 11.20 |
| Enterprise Value to EBITDA | -10.941 |
| Enterprise Value to Sales | 18.856 |
| Total Debt to Enterprise Value | 0.027 |
SEPN Efficiency
| Revenue/Employee | 353,469.231 |
| Income Per Employee | -375,992.308 |
| Receivables Turnover | 3.344 |
| Total Asset Turnover | 0.087 |
SEPN Liquidity
| Current Ratio | 4.727 |
| Quick Ratio | 4.727 |
| Cash Ratio | 4.499 |
SEPN Profitability
| Gross Margin | 96.509 |
| Operating Margin | -175.833 |
| Pretax Margin | -106.346 |
| Net Margin | -106.372 |
| Return on Assets | -9.235 |
| Return on Equity | -12.19 |
| Return on Total Capital | -12.052 |
| Return on Invested Capital | -11.542 |
SEPN Capital Structure
| Total Debt to Total Equity | 6.186 |
| Total Debt to Total Capital | 5.825 |
| Total Debt to Total Assets | 3.925 |
| Long-Term Debt to Equity | 5.607 |
| Long-Term Debt to Total Capital | 5.28 |